Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "DNTH103"


1 mentions found


Oppenheimer thinks a key treatment for a range of autoimmune diseases can be a growth catalyst for Dianthus Therapeutics stock. The firm initiated coverage of the clinical stage biotechnology company with an outperform rating and a $48 per share price target in a Wednesday note. DNTH YTD mountain Dianthus Therapeutics stock. He estimates a more than $20 billion market for this treatment. Investors will be able to gain insight into the treatment's effectiveness in clinical data that will begin to be released in mid-2025, Allred said.
Persons: Oppenheimer, Trevor Allred, Allred, DNTH103 Organizations: Dianthus Therapeutics, Therapeutics, pharma
Total: 1